(Lymphoma) Tucidinostat Receives Japan Manufacturing and Marketing Approval
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- July 5, 2021
- Reading time: 1 minute
On June 24, Meiji Seika Pharma Co., Ltd. announced that its partner company Huya Japan obtained Japan manufacturing and marketing approval on June 23 for the HDAC inhibitor tucidinostat, indicated for relapsed or refractory adult T-cell leukemia-lymphoma (ATL).
About Tucidinostat
Tucidinostat is an epigenetic immunomodulator — a benzamide-based oral drug that inhibits the enzymatic activity of HDAC1/2/3/10. It is believed that HDAC activity inhibition also suppresses histone deacetylation, inducing cell cycle arrest and apoptosis while inhibiting cell proliferation. Non-clinical study results suggest that in addition to inhibiting tumor cell proliferation, tucidinostat may also have immunomodulatory effects.
Approval Basis
The marketing approval was based on Phase 2b clinical trial results in Japanese patients with relapsed or refractory adult T-cell leukemia-lymphoma. The study was conducted by HUYABIO International, the parent company of Huya Japan, in partnership with Meiji Seika Pharma Co., Ltd.
Future Development
A variation application is currently being reviewed to expand the indication to include relapsed or refractory peripheral T-cell lymphoma (PTCL). The drug has been designated as an orphan drug for monotherapy treatment of PTCL and ATL. Phase 1/2 clinical trials are currently underway in the United States for tucidinostat in solid tumors.
Source: https://www.meiji-seika-pharma.co.jp/pressrelease/2021/detail/pdf/210624_01.pdf
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4